Galytx aims to deliver maximum clinical value from galectin-3 targeted therapy. Our pipeline of assets will enable us to deliver therapeutics for indications requiring either/both chronic and/or acute administration where necessary. This strategy will enable us to provide effective therapies for the broadest range of galectin-3 mediated diseases.